Supernus, Inc. (INDV) stock

INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SUPN

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30

$35.37+0.12 (+0.34%)

Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –

Supernus EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Supernus's EV/EBITDA was 9.4× on Nov 11, 2026, against 17.3× a year earlier. Over the last 2 years it ranged from 9.4× to 60.4×, with a median of 15.4×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	9.4×	−9.1
2025	Dec 31, 2025	18.5×	+8.4
2023	Feb 28, 2023	10.2×	−0.5
2022	Dec 30, 2022	10.7×	–

Where these numbers come from

Parsed from the XBRL in Supernus's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is INDV.

Compare: INDV vs ALKS · INDV vs ACAD · INDV vs COLL · INDV vs ANIP · INDV vs INSM

Revenue growth16.3% · median 14.8%

Gross margin85.0% · median 84.4%

Operating margin40.6% · median 10.2%

Net margin32.8% · median 4.7%

Company	Revenue	Growth
ALKS	$1.67B	+10.8%
INSM	$1.52B	+240.0%
INDV	$1.37B	+16.3%
ACAD	$1.20B	+14.8%
ANIP	$1.04B	+25.9%
COLL	$815.19M	+7.7%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 838
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1625297

Advertisement
300 × 250

See a number that looks wrong?

Supernus EV/EBITDA

EV/EBITDA at the end of each year

More Supernus figures